Human Casitas B-lineage lymphoma proto-oncogene b (CBL-B) is an E3 ubiquitin-protein ligase that functions as a negative regulator of T-cell activation. It is a promising drug target in cancer immunotherapy. The CBL-B TR-FRET Assay Kit is designed to measure CBL-B auto-ubiquitination activity in a homogeneous 384 reaction format. It utilizes biotin-labeled Ubiquitin and a terbium-labeled antibody recognizing the GST-tagged CBL-B protein to complete the TR-FRET pairing. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications.
The CBL-B TR-FRET Assay Kit is designed to measure CBL-B auto-ubiquitination activity in a homogeneous 384 reaction format.
Materials Required But Not Supplied
Fluorescent microplate reader capable of measuring Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Adjustable micropipettor and sterile tips
*The concentrations of E1, E2, and E3 enzymes are lot-specific and will be indicated on the tubes containing the enzyme.
UniProt #
UBE1: P22314; UBCH5b: P62837; CBL-B: Q13191
Background
CBL-B, a RING finger E3-ubiquitin ligase, acts as an intracellular checkpoint and a regulator of cytotoxic lymphocytes and NK cells. CBL-B binds E2-ubiqutin as well as target proteins such as TAM receptor TYRO3, forcing further degradation of TYRO3. CBL-B modulates innate immune responses and plays a key role in host defense to pathogens and anti-tumor immunity. Targeting CBL-B represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. CBL-B has emerged as a new target of interest in the field of immunotherapy due to its ability to suppress cancer immune-evasion. CBL-B initiates anti-cancer immune responses in NK cells in both cytotoxic and effector T cells, promoting T-cell and NK cell activation.
References
1. Jeon, M.S., et al., Immunity. 2004; 21(2): 167-177
2. Chiang, Y.J. et al., Nature. 2000; 403: 216-220
Storage/Stability
Stable at least 6 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival.
Applications
Great for screening small molecular inhibitors for drug discovery and HTS applications.
Shipping Temperature
-80°C
Warnings
Avoid freeze/thaw cycles.
Disclaimers and Limitations
BPS Bioscience assay kits are validated using the listed components according to our specific protocol. Any deviations to kit components or protocols, such as using different proteins, cell/tissue lysates, or buffers (including using the same component from other commercial sources) will void any warranties on the performance of the assay kit and is not recommended.
End-users should immediately report any issues to [email protected] upon receipt of the kit, such as missing components, damaged vials, no dry ice, etc.